Your email has been successfully added to our mailing list.

×
-0.00232018561484914 -0.00232018561484914 -0.00696055684454742 -0.00696055684454742 -0.00696055684454742 -0.00232018561484914 0.00178654292343404 -0.00696055684454742
Stock impact report

Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity Study in MS

FLEX PHARMA (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
Company Research Source: Business Wire
-- Company to Report Results Late Q1 2018 -- BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today announced that it has completed enrollment in its Phase 2 exploratory spasticity study in multiple sclerosis (MS) with approximately 50 patients in Australia. The randomized, placebo-controlled, blinded, cross-over study is designed to evaluate the safety and efficacy of FLX-787, the Company’s single molecule, chemically synthesized, dual A1/V1 transient receptor potential (TRPA1/V1) ion channel activator, in patients Show less Read more
Impact Snapshot
Event Time:
FLKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for FLKS alerts
Opt-in for
FLKS alerts

from News Quantified
Opt-in for
FLKS alerts

from News Quantified